Patients with type 2 diabetes mellitus have a twofold increased risk of cardiovascular mortality compared with non-diabetic individuals. There is a growing awareness that glycemic efficacy of anti-diabetic drugs does not necessarily translate to cardiovascular safety. Over the past few years, there has been a number of trials evaluating the cardiovascular effects of anti-diabetic drugs. In this...

Nanoparticulate imaging agents and therapeutics have proven to be valuable tools in preclinical cardiovascular disease research. Because of their distinct properties and significant functional versatility, nanoparticulate imaging agents afford certain capabilities that are typically not provided by traditional small molecule agents. This review is the second in a two-part series covering nanopa...

Failure of hemostasis and the formation blood clots in arteries are main reasons that provoke onset cardiovascular diseases (CVDs) such as myocardial infarction ischemic stroke. Cardiovascular have become primary cause deaths disabilities across globe. Therefore, this problem needs to be addressed with urgency. The disintegration requires fibrinolytic agents, which involved thrombolysis. Strept...

Background Patients referred to cardiac MRI (CMR) for suspicion of obstructive coronary artery disease typically undergo vasodilator stress testing using either adenosine or regadenoson. Both of these agents are effective and have been evaluated for stress testing in both the CMR and nuclear medicine setting but the cardiovascular physiologic effects of each of these agents have not been well s...

BACKGROUND A wide variety of oral diabetes medications are currently available for the treatment of type 2 diabetes mellitus, but it is unclear how these agents compare with respect to long-term cardiovascular risk. Our objective was to systematically examine the peer-reviewed literature on the cardiovascular risk associated with oral agents (second-generation sulfonylureas, biguanides, thiazol...

It is widely assumed in clinical practice that drug treatment associated with hypotension can result in falls and syncope, but there is actually very little evidence to support this. Therefore the data in all patients whose cardiovascular medications were stopped at a falls/syncope clinic were analysed to see if their symptoms were altered and if renewal of these medications was necessary at su...